Forbes' Matthew Herper predicts that the $1,000 genome will become a reality in 2010, "ushering in a new era of genetic medicine." Herper says that direct-to-consumer personalized genomics companies aren't "ready for prime time." Instead, he says that the traditional doctor-insurer-patient model will be more fruitful. The companies on his watch list include Illumina, Complete Genomics, Pacific Biosciences, and Ion Torrent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.